NASDAQ:DNLI - Denali Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.93 -0.05 (-0.25 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$19.98
Today's Range$19.53 - $20.17
52-Week Range$14.72 - $25.79
Volume87,993 shs
Average Volume157,278 shs
Market Capitalization$1.92 billion
P/E Ratio-3.38
Dividend YieldN/A
BetaN/A

About Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics logoDenali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548

Debt

Debt-to-Equity RatioN/A
Current Ratio21.99
Quick Ratio21.99

Price-To-Earnings

Trailing P/E Ratio-3.38
Forward P/E Ratio-26.93
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.71 per share
Price / Book3.49

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees130
Outstanding Shares94,440,000

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics (NASDAQ:DNLI) issued its quarterly earnings data on Friday, May, 11th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.13 by $0.39. The company had revenue of $0.64 million for the quarter, compared to analyst estimates of $45 million. View Denali Therapeutics' Earnings History.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Denali Therapeutics.

What price target have analysts set for DNLI?

4 equities research analysts have issued 1 year target prices for Denali Therapeutics' stock. Their predictions range from $23.00 to $25.00. On average, they anticipate Denali Therapeutics' share price to reach $24.00 in the next year. View Analyst Ratings for Denali Therapeutics.

Who are some of Denali Therapeutics' key competitors?

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the folowing people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 42)
  • Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 45)
  • Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 58)
  • Mr. Steve E. Krognes, CFO, Principal Accounting Officer & Treasurer (Age 49)
  • Dr. Carole Ho M.D., Chief Medical Officer & Head of Devel. (Age 45)

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

When does Denali Therapeutics' lock-up period expire?

Denali Therapeutics' lock-up period expires on Wednesday, June 6th. Denali Therapeutics had issued 13,888,888 shares in its public offering on December 8th. The total size of the offering was $249,999,984 based on an initial share price of $18.00. After the expiration of Denali Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Has Denali Therapeutics been receiving favorable news coverage?

News stories about DNLI stock have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Denali Therapeutics earned a news sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 44.78 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (5.50%), BlackRock Inc. (1.12%), Bamco Inc. NY (0.97%), Artal Group S.A. (0.48%), Lord Abbett & CO. LLC (0.30%) and Allianz Asset Management GmbH (0.25%). View Institutional Ownership Trends for Denali Therapeutics.

Which major investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Principal Financial Group Inc. and Artal Group S.A.. View Insider Buying and Selling for Denali Therapeutics.

Which major investors are buying Denali Therapeutics stock?

DNLI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bamco Inc. NY, Lord Abbett & CO. LLC, Baillie Gifford & Co., Northern Trust Corp, Schwab Charles Investment Management Inc., Legal & General Group Plc and Allianz Asset Management GmbH. View Insider Buying and Selling for Denali Therapeutics.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $19.93.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $1.92 billion. The company earns $-88,180,000.00 in net income (profit) each year or ($5.89) on an earnings per share basis. Denali Therapeutics employs 130 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 151 OYSTER POINT BLVD. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.


MarketBeat Community Rating for Denali Therapeutics (DNLI)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Denali Therapeutics (NASDAQ:DNLI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Denali Therapeutics in the last 12 months. Their average twelve-month price target is $24.00, suggesting that the stock has a possible upside of 20.42%. The high price target for DNLI is $25.00 and the low price target for DNLI is $23.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.752.752.75N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$24.00N/A
Price Target Upside: 20.42% upside53.45% upside53.45% upsideN/A

Denali Therapeutics (NASDAQ:DNLI) Consensus Price Target History

Price Target History for Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics (NASDAQ:DNLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/2/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00MediumView Rating Details
1/2/2018Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralHighView Rating Details
1/2/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$25.00HighView Rating Details
1/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$24.00HighView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Denali Therapeutics (NASDAQ:DNLI) Earnings History and Estimates Chart

Earnings by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics (NASDAQ:DNLI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS

Denali Therapeutics (NASDAQ DNLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2018        
5/11/2018Q1 2018$0.13($0.26)$45.00 million$0.64 millionViewN/AView Earnings Details
3/19/2018Q4 2017($0.2720)($0.74)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Denali Therapeutics (NASDAQ:DNLI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Denali Therapeutics (NASDAQ DNLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.30%
Institutional Ownership Percentage: 63.74%
Insider Trading History for Denali Therapeutics (NASDAQ:DNLI)
Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics (NASDAQ DNLI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Douglas K BrattonMajor ShareholderBuy275,000$18.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Denali Therapeutics (NASDAQ DNLI) News Headlines

Source:
DateHeadline
Bursting at the seams, this high-profile Peninsula biotech company is moving to a bigger home'Bursting at the seams,' this high-profile Peninsula biotech company is moving to a bigger home
www.bizjournals.com - May 21 at 9:23 AM
'Bursting at the seams,' this high-profile Peninsula biotech company is moving to a bigger home'Bursting at the seams,' this high-profile Peninsula biotech company is moving to a bigger home
finance.yahoo.com - May 21 at 9:23 AM
[$$] Life Sciences Investor Biomatics Capital Seeks $300 Million Second Fund[$$] Life Sciences Investor Biomatics Capital Seeks $300 Million Second Fund
finance.yahoo.com - May 19 at 9:30 AM
 Brokerages Anticipate Denali Therapeutics (DNLI) to Announce -$0.21 EPS Brokerages Anticipate Denali Therapeutics (DNLI) to Announce -$0.21 EPS
www.americanbankingnews.com - May 18 at 9:24 PM
BRIEF-Denali Therapeutics Reports Q1 Loss Of $0.26 Per ShareBRIEF-Denali Therapeutics Reports Q1 Loss Of $0.26 Per Share
www.reuters.com - May 12 at 4:21 PM
Denali Therapeutics (DNLI) Releases Quarterly  Earnings Results, Misses Estimates By $0.39 EPSDenali Therapeutics (DNLI) Releases Quarterly Earnings Results, Misses Estimates By $0.39 EPS
www.americanbankingnews.com - May 12 at 11:15 AM
Denali Therapeutics Reports First Quarter 2018 Financial ResultsDenali Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 10:35 AM
Denali Therapeutics (DNLI) Upgraded by ValuEngine to HoldDenali Therapeutics (DNLI) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 3 at 10:54 PM
Denali Therapeutics (DNLI) Given Average Rating of "Buy" by AnalystsDenali Therapeutics (DNLI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 2 at 3:34 AM
Zacks: Denali Therapeutics (DNLI) Given $25.33 Consensus Target Price by BrokeragesZacks: Denali Therapeutics (DNLI) Given $25.33 Consensus Target Price by Brokerages
www.americanbankingnews.com - April 26 at 3:16 AM
Zacks Investment Research Lowers Denali Therapeutics (DNLI) to HoldZacks Investment Research Lowers Denali Therapeutics (DNLI) to Hold
www.americanbankingnews.com - April 17 at 10:21 PM
 Denali Therapeutics (DNLI) Given $24.67 Average Price Target by Brokerages Denali Therapeutics (DNLI) Given $24.67 Average Price Target by Brokerages
www.americanbankingnews.com - April 9 at 5:35 AM
CytRx (CYTR) vs. Denali Therapeutics (DNLI) Head-To-Head AnalysisCytRx (CYTR) vs. Denali Therapeutics (DNLI) Head-To-Head Analysis
www.americanbankingnews.com - April 9 at 3:13 AM
Why Denali Therapeutics (DNLI) Could Shock the Market SoonWhy Denali Therapeutics (DNLI) Could Shock the Market Soon
www.zacks.com - April 5 at 8:54 AM
Denali Therapeutics (DNLI) Raised to Buy at Zacks Investment ResearchDenali Therapeutics (DNLI) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 3 at 11:30 PM
Denali Therapeutics (DNLI) Coverage Initiated by Analysts at Goldman SachsDenali Therapeutics (DNLI) Coverage Initiated by Analysts at Goldman Sachs
www.americanbankingnews.com - March 31 at 11:54 AM
Denali Therapeutics (DNLI) Earns Overweight Rating from Analysts at JPMorgan ChaseDenali Therapeutics (DNLI) Earns Overweight Rating from Analysts at JPMorgan Chase
www.americanbankingnews.com - March 31 at 11:54 AM
Denali Therapeutics (DNLI) Coverage Initiated at Morgan StanleyDenali Therapeutics (DNLI) Coverage Initiated at Morgan Stanley
www.americanbankingnews.com - March 31 at 11:54 AM
-$0.27 Earnings Per Share Expected for Denali Therapeutics Inc (DNLI) This Quarter-$0.27 Earnings Per Share Expected for Denali Therapeutics Inc (DNLI) This Quarter
www.americanbankingnews.com - March 28 at 11:20 AM
Zacks: Denali Therapeutics Inc (DNLI) Given Average Recommendation of "Buy" by BrokeragesZacks: Denali Therapeutics Inc (DNLI) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 25 at 11:32 PM
 Denali Therapeutics Inc (DNLI) Given $24.67 Consensus Target Price by Analysts Denali Therapeutics Inc (DNLI) Given $24.67 Consensus Target Price by Analysts
www.americanbankingnews.com - March 21 at 3:48 PM
Heres When You Can Buy Twitters StockHere's When You Can Buy Twitter's Stock
finance.yahoo.com - March 20 at 4:14 PM
Denali Therapeutics (DNLI) Issues  Earnings ResultsDenali Therapeutics (DNLI) Issues Earnings Results
www.americanbankingnews.com - March 20 at 10:41 AM
Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business HighlightsDenali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights
finance.yahoo.com - March 19 at 9:46 AM
Analysts Anticipate Denali Therapeutics Inc (DNLI) to Announce ($0.30) EPSAnalysts Anticipate Denali Therapeutics Inc (DNLI) to Announce ($0.30) EPS
www.americanbankingnews.com - March 18 at 9:28 AM
 Denali Therapeutics Inc (DNLI) Receives Consensus Rating of "Buy" from Brokerages Denali Therapeutics Inc (DNLI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 14 at 7:32 PM
 Analysts Expect Denali Therapeutics Inc (DNLI) to Announce -$0.30 EPS Analysts Expect Denali Therapeutics Inc (DNLI) to Announce -$0.30 EPS
www.americanbankingnews.com - March 11 at 5:18 AM
 Denali Therapeutics Inc (DNLI) Receives Average Recommendation of "Strong Buy" from Analysts Denali Therapeutics Inc (DNLI) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 8 at 9:29 PM
Flagship Pioneering Inc. Acquires Shares of 8,918,749 Denali Therapeutics Inc (DNLI)Flagship Pioneering Inc. Acquires Shares of 8,918,749 Denali Therapeutics Inc (DNLI)
www.americanbankingnews.com - March 6 at 2:58 PM
Zacks: Analysts Set $24.67 Price Target for Denali Therapeutics Inc (DNLI)Zacks: Analysts Set $24.67 Price Target for Denali Therapeutics Inc (DNLI)
www.americanbankingnews.com - March 3 at 5:32 AM
Denali Therapeutics (DNLI) versus Recro Pharma (REPH) Head-To-Head ContrastDenali Therapeutics (DNLI) versus Recro Pharma (REPH) Head-To-Head Contrast
www.americanbankingnews.com - March 1 at 3:18 AM
 Analysts Expect Denali Therapeutics Inc (DNLI) to Post -$0.30 Earnings Per Share Analysts Expect Denali Therapeutics Inc (DNLI) to Post -$0.30 Earnings Per Share
www.americanbankingnews.com - February 22 at 11:50 AM
Zacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 12 at 11:28 PM
Zacks: Denali Therapeutics Inc (DNLI) Given $24.67 Average Target Price by AnalystsZacks: Denali Therapeutics Inc (DNLI) Given $24.67 Average Target Price by Analysts
www.americanbankingnews.com - February 9 at 9:28 PM
Denali Therapeutics (DNLI), Lonza Pharma & Biotech Announce Pact to Develop and Produce Biologic MedicinesDenali Therapeutics (DNLI), Lonza Pharma & Biotech Announce Pact to Develop and Produce Biologic Medicines
www.streetinsider.com - February 9 at 9:08 AM
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic MedicinesDenali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
finance.yahoo.com - February 8 at 4:28 PM
Zacks: Denali Therapeutics Inc (DNLI) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Denali Therapeutics Inc (DNLI) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 25 at 11:40 AM
Analyzing Denali Therapeutics (DNLI) & Its RivalsAnalyzing Denali Therapeutics (DNLI) & Its Rivals
www.americanbankingnews.com - January 19 at 9:30 PM
 Brokerages Anticipate Denali Therapeutics Inc (DNLI) Will Announce Earnings of -$0.30 Per Share Brokerages Anticipate Denali Therapeutics Inc (DNLI) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - January 19 at 11:38 AM
Short Interest in Denali Therapeutics Inc (DNLI) Expands By 1,101.8%Short Interest in Denali Therapeutics Inc (DNLI) Expands By 1,101.8%
www.americanbankingnews.com - January 12 at 2:38 AM
Denali Therapeutics Incs Quiet Period Set To End  on January 17th (NASDAQ:DNLI)Denali Therapeutics Inc's Quiet Period Set To End on January 17th (NASDAQ:DNLI)
www.americanbankingnews.com - January 10 at 1:04 AM
Analysts Anticipate Denali Therapeutics Inc (DNLI) to Announce ($0.30) Earnings Per ShareAnalysts Anticipate Denali Therapeutics Inc (DNLI) to Announce ($0.30) Earnings Per Share
www.americanbankingnews.com - January 9 at 7:58 AM
Denali Therapeutics (DNLI) Reports Collaboration with Takeda Pharmaceutical to Develop & Commercial for Neurodegenerative DiseasesDenali Therapeutics (DNLI) Reports Collaboration with Takeda Pharmaceutical to Develop & Commercial for Neurodegenerative Diseases
www.streetinsider.com - January 5 at 8:15 AM
Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative DiseasesTakeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases
finance.yahoo.com - January 5 at 8:15 AM
Snow, Skiing, And A Biotech VCs Outlook For 2018Snow, Skiing, And A Biotech VC's Outlook For 2018
finance.yahoo.com - January 4 at 6:30 PM
Denali Therapeutics (DNLI) and Its Peers Critical ContrastDenali Therapeutics (DNLI) and Its Peers Critical Contrast
www.americanbankingnews.com - January 4 at 11:30 AM
Zacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 4 at 4:02 AM
Analyst: Denali Therapeutics Neuroscience Work Could Lead To Near-Term UpsideAnalyst: Denali Therapeutics' Neuroscience Work Could Lead To Near-Term Upside
finance.yahoo.com - January 3 at 6:34 PM
3 Key Questions For Denali Therapeutics Investors3 Key Questions For Denali Therapeutics Investors
finance.yahoo.com - January 3 at 7:56 AM
Denali Therapeutics Inc. (DNLI) Coverage Initiated by Analysts at Evercore ISIDenali Therapeutics Inc. (DNLI) Coverage Initiated by Analysts at Evercore ISI
www.americanbankingnews.com - January 2 at 8:48 AM

SEC Filings

Denali Therapeutics (NASDAQ:DNLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Denali Therapeutics (NASDAQ DNLI) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.